The estimated Net Worth of Franco Valle is at least $1.01 Million dollars as of 11 January 2021. Franco Valle owns over 3,247 units of Eidos Therapeutics Inc stock worth over $213,501 and over the last 5 years Franco sold EIDX stock worth over $797,906.
Sign up
Franco Valle EIDX stock SEC Form 4 insiders trading
Franco has made over 6 trades of the Eidos Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Franco exercised 3,247 units of EIDX stock worth $23,508 on 11 January 2021.
The largest trade Franco's ever made was selling 10,643 units of Eidos Therapeutics Inc stock on 7 October 2020 worth over $797,906. On average, Franco trades about 3,189 units every 39 days since 2020. As of 11 January 2021 Franco still owns at least 1,747 units of Eidos Therapeutics Inc stock.
You can see the complete history of Franco Valle stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Franco Valle's mailing address?
Franco's mailing address filed with the SEC is C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2000, SAN FRANCISCO, CA, 94104.
Insiders trading at Eidos Therapeutics Inc
Over the last 6 years, insiders at Eidos Therapeutics Inc have traded over $18,169,563 worth of Eidos Therapeutics Inc stock and bought 30,345,136 units worth $349,599,962 . The most active insiders traders include Capital Management, L.P.Ra ..., Pharma, Inc. Bridge Bio und Rajeev M. Shah. On average, Eidos Therapeutics Inc executives and independent directors trade stock every 13 days with the average trade being worth of $52,576,942. The most recent stock trade was executed by Pharma, Inc. Bridge Bio on 26 January 2021, trading 14,428,836 units of EIDX stock currently worth $1,763,348,048.
What does Eidos Therapeutics Inc's logo look like?
Complete history of Franco Valle stock trades at Eidos Therapeutics Inc
Eidos Therapeutics Inc executives and stock owners
Eidos Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Cameron Turtle,
Chief Business Officer -
William Lis,
Independent Director -
Uma Sinha,
Chief Scientific Officer, Director -
Ali Satvat,
Independent Director -
Neil Kumar,
Chief Executive Officer, Director -
Douglas Rohlen,
Independent Director -
Suzanne Hooper,
Independent Director -
Jonathan Fox,
President, Chief Medical Officer -
Franco Valle,
Senior Vice President, Finance -
Rajeev M. Shah,
Director -
Capital Management, L.P.Ra ...,
-
Christine Siu,
CFO and Secretary -
Hoyoung Huh,
Director -
Pharma, Inc. Bridge Bio,
10% owner -
Eric Aguiar,
Director